283. 後天性赤芽球癆 Disease details / Clinical trials / Drug dev / DR info

AF37702 injection
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom
AF37702, hematide
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom
Alemtuzumab
   University of Calgary
      2017   Phase 2   NCT03214354   Canada
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Autologous peripheral blood stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Bortezomib/dexamethasone
   Institute of Hematology & Blood Diseases Hospital, China
      2020   Phase 2   NCT04423367   China
Campath, chemo and/or TBI allo SCT
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States
Cell infusion
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
Cyclophosphamide + pred
   Chulalongkorn University
      2009   Phase 3   NCT01288131   Thailand
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Cyclosporine A
   Bing Han
      2020   Phase 4   NCT04470804   China
Cyclosporine combine with mycophenolate mofetil
   Chulalongkorn University
      2009   Phase 3   NCT01288131   Thailand
Daclizumab
   Neal Young, M.D.
      1999   Phase 2   NCT00001962   United States
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Fludarabine
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Fludarabine phosphate
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
Hematide, peginesatide
   Takeda Development Centre Europe Ltd
      2006   Phase 2   EUCTR2005-004944-30-GB   Germany;United Kingdom
      2006   Phase 2   EUCTR2005-004944-30-DE   Germany;United Kingdom
Isatuximab
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05559827   -
Laboratory biomarker analysis
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
Leucine
   Northwell Health
      2013   Phase 1/Phase 2   NCT01362595   United States
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Mycophenolate mofetil
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Peginesatide
   Takeda
      2006   Phase 2   NCT00314795   France;Germany;United Kingdom
Peripheral blood stem cell transplantation
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
POST-transplant G-CSF
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Rabbit ATG
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
Rapamycin
   Soochow hopes hematonosis hospital
      2022   Phase 2-3   ChiCTR2200065107   China
Rituximab
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00229619   United States
Sirolimus
   Bing Han
      2020   Phase 4   NCT04470804   China
      2018   Phase 4   NCT03364764   China
   Nakazawa Hideyuki
      2023   Phase 2   JPRN-jRCTs031230310   -
   University of Calgary
      2017   Phase 2   NCT03214354   Canada
Tacrolimus
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03918265   China
      2018   Phase 4   NCT03540472   China
Total body irradiation
   Masonic Cancer Center, University of Minnesota
      2024   Phase 2   NCT06412497   United States
   University of Calgary
      2017   Phase 2   NCT03214354   Canada
Total-body irradiation
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
Trifluoperazine
   Adrianna Vlachos
      2019   Phase 1/Phase 2   NCT03966053   United States